摘要原发性青光眼发病机制尚不明确,且治疗棘手.微小RNA(miRNA)是小分子非编码RNA,能特异性地抑制靶mRNA,对基因转录后的表达进行调控,在细胞的增生、凋亡、分化、个体发育以及机体代谢等过程中扮演重要角色.近几年研究发现,miRNA在房水分泌、昼夜眼压波动、小梁网结构重塑以及手术后滤过道瘢痕形成、促进神经再生等青光眼发病和治疗过程的中间环节有重要的调控作用.本文就miRNA在青光眼发病及治疗中的作用机制进行综述,对抗青光眼药物靶点研究的前景进行展望.

abstractsNowadays,the pathogenesis of primary glaucoma is unclear yet,and the treatment is tricky.MicroRNA (miRNA) is a small molecule non-coding RNA,which could inhibit the target mRNA,specifically.miRNA can regulate post-transcriptional expression,and it plays an important role in the process of cell proliferation,apoptosis,differentiation,orgnic development and metabolism.Researches in recent years found that miRNA plays an important regulatory role in the process of glaucoma,such as aqueous secretion,intraocular pressure fluctuation,trabecular meshwork remodeling,anti-glaucoma surgery filtration scarring and nerve regeneration.In this review,we summarized the mechanism of miRNA in glaucomatous lesions,and looked ahead to the future of drug targeting research in glaucoma.